Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible;La terapia medica dell'ischemia critica degli arti inferiori non immediatamente rivascolarizzabile

Giornale Italiano di Cardiologia

Volumn 7, Issue 5, 2006, Pages 317-335

  Melillo, Elio ^a   Nuti, Marco ^a   Buttitta, Flavio ^a   Balbarini, Alberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Diabetes mellitus; Iloprost; Ischemia; Mortality

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; BUFLOMEDIL; CALCIUM ANTAGONIST; CARBON DIOXIDE; CHOLESTEROL; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ILOPROST; NAFTIDROFURYL; NIFEDIPINE; OXYGEN; PENTOXIFYLLINE; PLACEBO; PLASMID DNA; PROSTAGLANDIN E1; TICLOPIDINE; VASCULOTROPIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; VASODILATOR AGENT;

ANGIOGENESIS; ARTERY DISEASE; ARTICLE; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; EARLY DIAGNOSIS; ENDOVASCULAR SURGERY; EXPERIENCE; FOLLOW UP; GENE THERAPY; HEART DEATH; HUMAN; HYPERBARIC OXYGEN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEG AMPUTATION; LEG ISCHEMIA; LEG REVASCULARIZATION; LIMB SALVAGE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; RECANALIZATION; REMISSION; SPINAL CORD STIMULATION; STEM CELL TRANSPLANTATION; SYMPTOM; TRANSCUTANEOUS CARBON DIOXIDE MONITORING; TRANSCUTANEOUS OXYGEN MONITORING; TREATMENT OUTCOME; VASODILATATION; ADOLESCENT; ADULT; AGED; ALGORITHM; AMPUTATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; FEMALE; ISCHEMIA; LEG; MALE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TIME; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ALPROSTADIL; AMPUTATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; ILOPROST; ISCHEMIA; LEG; LIMB SALVAGE; MALE; META-ANALYSIS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TIME FACTORS; VASODILATOR AGENTS;

EID: 33745246064     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Second European Consensus Document on chronic critical leg ischemia. Eur J Vase Surg 1992; 6 (Suppl A): 1-32.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASQ. J Vase Surg 2000; 31 (Pt 2): S1-S296.
3. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002; 25: 113-20.
4. Matzke S, Lepantalo M. Claudication does not always precede critical leg ischemia. Vasc Med 2001; 6: 77-80.
5. Fowkes FGR, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epiderniol 1991; 20: 384-92.
6. Kannel WB, Skinner JJ Jr, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham study. Circulation 1970; 41: 875-83.
7. Meijer WT, Hoes AW, Rutgers DM, Bots ML, Holman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vase Biol 1998; 18: 185-92.
8. Brevetti G, Oliva G, Silvestro A, et al, for the Peripheral Arteriopathy and Cardiovascular Events (PACE) Study Group. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis 2004; 175: 131-8.
9. Dormandy JA, Murray GD. The fate of the claudicant: a prospective study of 1969 claudicants. Eur J Vase Surg 1991; 5: 131-3.
10. Melillo E, Nuti M, Bongiorni L, Golgini E, Balbarini A. Tassi di amputazione maggiore e minore ed ischemia critica degli arti inferiori: dati epidentiologici dalla toscana occidentale. Ital Heart J 2004; 5: 794-805.
11. Dormandy J, Heeck L, Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 1999; 12: 138-41.
12. Wolfe JN. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 1986; 73: 321.
13. Melillo E, Nuti M, Buttitta F, et al. Salvataggio d'arto farmacologico mediante iloprost nella ischemia critica degli arti inferiori non rivascolarizzabile: conferme e modifiche della nostra condotta terapeutica negli ultimi otto anni. Minerv Cardioangiol 2003; 51 (Suppl 1): 253-55.
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
15. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25: 166-81.
16. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25: 742-8.
17. Ostergren J, Sleight P, Dagenais G, et al, for the HOPE Study Investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17-24.
18. Melillo E. La diagnostica microcircolatoria. In: Manusia F, ed. La malattia ischemica periferica. Grosseto, Edizioni Aurelia, 2001: 77-90.
19. Rooke TW, Osmundson PJ. Variability and reproducibility of transcutaneous oxygen tension measurements in the assessment of peripheral vascular disease. Angiology 1989; 40: 695-700.
20. Melillo E, Catapano G, Ferrari M, Pedrinelli R. Transcutaneous oxygen tension measurement in patients with chronic arterial obstructive disease: reliability and long-term variability of the method. Angiology 1994; 45: 469-75.
21. 2) in peripheral arterial occlusive disease (a review of the methodological and clinical literature with a special reference to critical limb ischaemia). Vasa 1992; 21: 111-26.
22. Ubbink DT, Spincemaille GH, Reneman RS, Jacobs MJ. Prediction of imminent amputation in patients with non-reconstructible leg ischemia by means of microcirculatory investigations. J Vasc Surg 1999; 30: 114-21.
23. Melillo E, Catapano G, Dell'Omo G, et al. Transcutaneous oxygen and carbon dioxide measurement in peripheral vascular disease. Vasc Surg 1995; 29: 273-80.
24. Melillo E, Nuti M, Pedrinelli R, Ferrari M, Balbarini A. Prognostic values of transcutaneous oxygen and carbon dioxide measurements in patients with lower limb critical ischaemia. (abstr) Eur Heart J 2005; 26: 701.
25. Criqui MH. Sistemic atherosclerotic risk and the mandate for intervention in atherosclerotic peripheral arterial disease. Am J Cardiol 2001; 88: 43J-47J, 2001.
26. Vecht RJ, Nicolaides AN, Brandao E, et al. Resting and treadmill electrocardiographic findings in patients with intermittent claudication. Int J Angiol 1982; 1: 119-21.
27. Brewster DC, Okada RD, Strauss HW, Abbott WM, Darling RC, Boucher CA. Selection of patients for preoperative coronary angiography: use of dipyridamole-stress-thallium myocardial imaging. J Vasc Surg 1985; 2: 504-10.
28. Hertzer NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199: 223-33.
29. Hughson WG, Mann JI, Tibbs DJ, Woods HF, Walton I. Intermittent claudication: factors determining outcome. BMJ 1978; 1: 1377-79.
30. Alexandrova NA, Gibson WC, Norris JW, Maggesano R. Carotid artery stenosis in peripheral vascular disease. J Vasc Surg 1996; 23: 645-9.
31. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12: 209-15.
32. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-8.
33. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
34. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effects of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases: a double-blind study versus placebo. Angiology 1982; 33: 357-67.
35. Jorneskog G, Brismar K, Fagrell B. Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients. Vasa 1993; 22: 137-42.
36. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992; 127: 1112-5.
37. The European Study Group. Intravenous pentoxifylline for the treatment of chronic critical limb ischemia. Eur J Vase Endovasc Surg 1995; 9: 426-36.
38. Norwegian Pentoxifylline Multicenter Trial Group. Efficacy and clinical tolerance of parenteral pentoxifylline in the treatment of critical lower limb ischernia. A placebo controlled multicenter study. Int Angiol 1996; 15: 75-80.
39. Fagrell B, Hermansson IL. Effect of buflomedil on microcirculation of the skin in acral gangrene. Fortschr Med 1985; 103: 23-7.
40. Greenhalgh RM. Naftidrofuryl for ischemic rest pain: a controlled trial. Br J Surg 1981; 68: 265-6.
41. Dormandy J. Clinical use of calcium antagonists in peripheral circulatory disease. Ann NY Acad Sci 1988; 522: 611-20.
42. Bode-Boger SM, Boger RH, Alfke H, et al. L-arginine induces nitric oxide-dependent vasodilatation in patients with critical limb ischemia: a randomized, controlled study. Circulation 1996; 93: 85-90.
43. Nilsson L, Apelqvist J, Edvinsson L. Effects of alpha-trinositol on peripheral circulation in diabetic patients with critical limb ischaemia. A pilot study using laser Doppler fluxmetry, transcutaneous oxygen tension measurements and dynamic capillaroscopy. Eur J Vase Endovasc Surg 1998; 15: 331-6.
44. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-50.
45. Isner JM, Walsh K, Symes JF, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995; 91: 2687-92.
46. Baumgartner I, Pieczeck A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
47. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003; 114: 85-92.
48. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
49. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-7.
50. Tateishi-Yuyama E, Matsubara H, Murohara T, et al, for the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427-35.
51. Minamino T, Toko H, Tateno K, Nagai T, Komuro I. Peripheral-blood or bone-marrow mononuclar cells for therapeutic angiogenesis? Lancet 2002; 360: 2083-4.
52. Inaba S, Egashira K, Komori K. Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis? (letter) Lancet 2002; 360: 2083.
53. Lenk K, Adams V, Lurz P, et al, Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaernia. Eur Heart J 2005; 26: 1903-9.
54. Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994; 13: 133-42.
55. Trubestein G, Diehm C, Gruss JD, Horsch S. Prostaglandin E1 in chronic arterial disease: a multicenter study. Vasa 1987; 17 (Suppl): 39-43.
56. Alstaedt HO, Berzewski B, Breddin HK, et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 573-8.
57. The ICAI Study Group. Prostanoids for chronic critical leg ischaemia: a randomized, controlled, open-label trial with pros taglandin E1. Ann Intern Med 1999; 130: 412-21.
58. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinctic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992; 43: 889-924.
59. Pola R, Gaetani E, Flex A, et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possibile role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004; 36: 363-70.
60. GISAP Study. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). Int Angiol 1994; 13: 70-4.
61. Staben P, Albring M. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 327-33.
62. Beischer W, Dembski JC, Gruss JD, et al. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. Vasa 1998; 27: 15-9.
63. Duthois S, Cailleux N, Benosman B, Levesque H. Tolerance of iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diabetes Metab 2003; 29: 36-43.
64. Melillo E, Iabichella L, Berchiolli R, et al. Transcutaneous oxygen and carbon dioxide during treatment of critical limb ischemia with iloprost, a prostacyclin derivative. Int J Microcirc 1995; 15: 60-4.
65. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CF, Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Methodology Group. Circulation 1999; 100: 75-81.
66. Decks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004; 329: 168-9.
67. Melillo E, Ferrari M, Balbarini A, Pedrinelli R. Transcutaneous gases determination in diabetic critical limb ischemia. Diabetes Care 2005; 28: 2081-2.